Percutaneous Radiofrequency Ablation of Sonographically Unidentifiable Liver Tumors
Yasunori Minami, Hitoshi Shiozaki(Kindai University), Masatoshi Kudo(Kindai University), Satoshi Kitai(Kindai University), Shunsuke Takahashi(Kanagawa Dental University), Kuzuomi Ueshima(Kindai University), Toyokazu Fukunaga, Kinuyo Hatanaka(Union Hospital), Tatsuo Inoue, H. Hagiwara, Taisuke Ueda(Kindai University), Hobyung Chung(Kindai University)
Cited by 52
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Development of a Prokaryotic Universal Primer for Simultaneous Analysis of Bacteria and Archaea Using Next-Generation Sequencing
|PLoS ONE|2014|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k